keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis definition

keyword
https://www.readbyqxmd.com/read/28249066/global-skin-disease-morbidity-and-mortality-an-update-from-the-global-burden-of-disease-study-2013
#1
Chante Karimkhani, Robert P Dellavalle, Luc E Coffeng, Carsten Flohr, Roderick J Hay, Sinéad M Langan, Elaine O Nsoesie, Alize J Ferrari, Holly E Erskine, Jonathan I Silverberg, Theo Vos, Mohsen Naghavi
Importance: Disability secondary to skin conditions is substantial worldwide. The Global Burden of Disease Study 2013 includes estimates of global morbidity and mortality due to skin diseases. Objective: To measure the burden of skin diseases worldwide. Data Sources: For nonfatal estimates, data were found by literature search using PubMed and Google Scholar in English and Spanish for years 1980 through 2013 and by accessing administrative data on hospital inpatient and outpatient episodes...
March 1, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28223746/could-psoriatic-arthritis-be-easily-diagnosed-from-current-suspicious-physical-findings-in-the-dermatology-clinic
#2
Jee Woong Choi, Bo Ri Kim, Eunmi Seo, Sang Woong Youn
BACKGROUND: The prevalence and clinical characteristics of psoriatic arthritis (PsA) in patients with psoriasis are not well described in Asian populations, including Koreans. OBJECTIVE: The purpose of this study was to investigate the prevalence of PsA by using the classification of psoriatic arthritis (CASPAR) criteria on the basis of physical examination only, as well as its correlation with psoriasis severity and other medical conditions including nail psoriasis...
February 2017: Annals of Dermatology
https://www.readbyqxmd.com/read/28168661/psoriasis-in-systemic-lupus-erythematosus-a-single-center-experience
#3
Konstantinos Tselios, Kristy Su-Ying Yap, Rattapol Pakchotanon, Ari Polachek, Jiandong Su, Murray B Urowitz, Dafna D Gladman
The coexistence of psoriasis with systemic lupus erythematosus (SLE) has been reported in limited case series, raising hypotheses about shared pathogenetic mechanisms. Nevertheless, important differences regarding treatment do exist. The aim of the present study was to determine the prevalence and characteristics of psoriasis in a defined cohort of lupus patients. Patients with psoriasis were retrieved from the University of Toronto Lupus Clinic from its inception in 1970 up to 2015. Charts were hand-searched to collect information concerning demographic, clinical, and therapeutic variables...
February 6, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28092253/-mexican-treatment-goals-for-plaque-psoriasis
#4
Lorena Estrada-Aguilar, Mario Amaya-Guerra, Minerva Gómez-Flores, Esther Guevara-Sanginés, Fermín Jurado-Santacruz, Adriana Lopeztello-Santillán, César Maldonado-García, Mónica Rivera-Gómez, Norma Rodríguez-Martínez, Luis Vega-González
Psoriasis is a chronic inflammatory disease with a worldwide prevalence between 6 and 39% in moderate to severe forms. In European countries like Germany and England was identified that only one third of patients with moderate to severe forms will receive systemic management, this fact motivated to integrate into Europe an international consensus on treatment goals with the aim of providing support to the dermatologist by algorithms that serve as a therapeutic guide that allows you to gain control short and long term effects of this disease...
January 2017: Revista Médica del Instituto Mexicano del Seguro Social
https://www.readbyqxmd.com/read/28064543/itolizumab-a-novel-anti-cd6-monoclonal-antibody-a-safe-and-efficacious-biologic-agent-for-management-of-psoriasis
#5
Sunil Dogra, Shraddha Uprety, Swaroop Hassan Suresh
Psoriasis, a chronic immune-mediated skin disorder is associated with significant physical, psychological, and quality of life impairments. Along with well-documented genetic and environmental factors, immunological factors also contribute to the pathogenesis of psoriasis. Among the immunological factors, CD6 - dependent T-cell proliferation to form Th1 and Th17 cells play a major role in the pathogenesis of psoriasis. Itolizumab is the first humanized IgG1 monoclonal antibody, which selectively targets CD6...
January 25, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28058749/is-psoriasis-an-autoimmune-disease-interpretations-from-an-immunofluorescence-based-study
#6
Shashi Anand, Parikshaa Gupta, Ranjeet Bhardwaj, Tarun Narang, Sunil Dogra, Ranjana W Minz, Biman Saikia, Seema Chhabra
INTRODUCTION: Psoriasis is a multisystem, immune-mediated inflammatory disease. Some authors have proposed an autoimmune basis for psoriasis; however, till date, it has not been definitely established. This study was conducted to explore the autoimmune nature of psoriasis. MATERIALS AND METHODS: This was a prospective study in which 43 psoriasis patients were assessed for detailed clinical, histopathological and immunopathological features to explore the diagnostic utility of subtypes, intensity and number of immunoreactants in lesional and non-lesional skin in these patients...
January 5, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/28027825/inflammatory-bowel-disease-among-patients-with-psoriasis-treated-with-ixekizumab-a-presentation-of-adjudicated-data-from-an-integrated-database-of-7-randomized-controlled-and-uncontrolled-trials
#7
Kristian Reich, Craig Leonardi, Richard G Langley, Richard B Warren, Hervé Bachelez, Ricardo Romiti, Mamitaro Ohtsuki, Wen Xu, Nayan Acharya, Kathleen Solotkin, Jean-Frederic Colombel, Dana S Hardin
BACKGROUND: Inflammatory bowel disease (IBD) occurs more frequently in patients with psoriasis. The 2 diseases have significant genetic overlap, but the pathogenesis underlying their co-occurrence is unknown. OBJECTIVE: We sought to report adjudicated IBD cases (Crohn's disease [CD] and ulcerative colitis [UC]) in patients exposed to ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A. METHODS: Adverse events (AEs) integrated from 7 randomized controlled and uncontrolled trials were analyzed for the controlled induction period, controlled maintenance period, and all ixekizumab-treated patients...
December 24, 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27931515/autologous-adipose-derived-mesenchymal-stromal-cells-for-the-treatment-of-psoriasis-vulgaris-and-psoriatic-arthritis-a-case-report
#8
Miguel M De Jesus, Jayson S Santiago, Camille V Trinidad, Melvin E See, Kimberly R Semon, Manuel O Fernandez, Francisco S Chung
Psoriasis is a dermatologic disease of immune origins with no definitive cure. We report the Makati Medical Center experience of utilizing autologous mesenchymal stromal cells (MSCs) for one patient with psoriasis vulgaris (PV) and another with psoriatic arthritis (PA). Patients were educated and gave informed consent, according to the principles of the Declaration of Helsinki. The protocol was approved by the Cellular Transplantation Ethics Committee of the Makati Medical Center. Autologous MSCs were cultured from lipoaspirate and expanded in a clean room class 100 facility (Cellular Therapeutics Center, Makati Medical Center)...
November 2016: Cell Transplantation
https://www.readbyqxmd.com/read/27828627/inflammasomes-and-dermatology
#9
Daniel Coelho de Sá, Cyro Festa
Inflammasomes are intracellular multiprotein complexes that comprise part of the innate immune response. Since their definition, inflammasome disorders have been linked to an increasing number of diseases. Autoinflammatory diseases refer to disorders in which local factors lead to the activation of innate immune cells, causing tissue damage when in the absence of autoantigens and autoantibodies. Skin symptoms include the main features of monogenic inflammasomopathies, such as Cryopyrin-Associated Periodic Syndromes (CAPS), Familial Mediterranean Fever (FMF), Schnitzler Syndrome, Hyper-IgD Syndrome (HIDS), PAPA Syndrome, and Deficiency of IL-1 Receptor Antagonist (DIRA)...
September 2016: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/27795221/-acute-generalized-exanthematous-pustulosis-induced-by-piroxicam
#10
Ingrid Bissinger, Gustavo Matute-Turizo, María Natalia Mejía-Barreneche
BACKGROUND: Between 62 and 90% of cases of acute generalized exanthematous pustulosis are caused by drugs. Its onset is rapid with generalized pustules, fever, and blood neutrophil count over 7000; pustules resolve spontaneously in less than 15 days. A case associated with piroxicam described. CASE REPORT: A 36-year-old with initial erythema of the thorax and abdomen, accompanied by burning, without fever, which later spread to his forearms, upper arms, and thighs, with face edema...
October 2016: Revista Alergia Mexico: Organo Oficial de la Sociedad Mexicana de Alergia e Inmunología, A.C
https://www.readbyqxmd.com/read/27747942/clinical-pharmacology-of-citrus-bergamia-a-systematic-review
#11
REVIEW
Carmen Mannucci, Michele Navarra, Fabrizio Calapai, Raffaele Squeri, Sebastiano Gangemi, Gioacchino Calapai
Citrus bergamia Risso et Poiteau ("Bergamot") originated from the Mediterranean ecoregion (southern Italy, Calabria). Bergamot essential oil (BEO) is used in perfumes, cosmetics, and for stress reduction. Juice from C. bergamia has been used for hyperlipidemia. We evaluated literature published on C. bergamia clinical applications. Clinical trials on C. bergamia not combined with other substances, published in English, were searched. We selected ten articles, six describing BEO effects on stress, three reporting effects of polyphenolic fraction of C...
January 2017: Phytotherapy Research: PTR
https://www.readbyqxmd.com/read/27741337/therapeutic-synergy-neutrality-and-antagonism-combination-treatment-in-dermatology
#12
Mark A Strom, Girish C Mohan, Peter A Lio
Dermatologists frequently employ combination therapy to treat various diseases, but the evidence to support the use of such combinations is often lacking. Synergy is an appealing although somewhat ambiguous concept in medicine. Utilizing synergy allows clinicians to provide the most efficacious combination of treatments to patients, while potentially minimizing adverse effects and reducing the development of drug resistance. Definitions of synergy vary, but ultimately converge on finding a therapeutic advantage in combining treatments...
October 1, 2016: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/27693008/risk-of-serious-infections-cutaneous-bacterial-infections-and-granulomatous-infections-in-patients-with-psoriasis-treated-with-anti-tumor-necrosis-factor-agents-versus-classic-therapies-prospective-meta-analysis-of-psonet-registries
#13
Ignacio Garcia-Doval, Arnon D Cohen, Simone Cazzaniga, Ilan Feldhamer, Antonio Addis, Gregorio Carretero, Carlos Ferrándiz, Robert S Stern, Luigi Naldi
BACKGROUND: Anti-tumor necrosis factor (TNF) therapy in psoriasis has been associated with an increased risk of serious infections compared with nonbiologic systemic therapies. OBJECTIVE: We sought to quantify the risk of: (1) serious infections (leading to hospitalization, sequelae, or death); and (2) "any infection," bacterial cutaneous infections, and granulomatous infections among patients receiving anti-TNF therapy compared with nonbiologics (acitretin, methotrexate, cyclosporine)...
February 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27671245/treatment-satisfaction-among-patients-with-psoriasis-at-a-large-academic-center-an-observational-study
#14
Toral S Vaidya, Ali Alikhan
INTRODUCTION: Treatment goals depend on individual definitions of "treatment success" and tend to differ between patients and physicians. Patients who do not meet their own treatment goals, but do meet provider definitions of well-controlled disease, may be inappropriately placed on stable treatment regimens. METHODS: Patients with psoriasis on stable treatment regimens were queried about perceptions of disease control, improvement level, overall treatment satisfaction, and consideration for trying new treatments...
September 27, 2016: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/27579746/porokeratosis-ptychotropica-a-rare-manifestation-with-typical-histological-exam
#15
John Verrinder Veasey, Monique Coelho Dalapicola, Rute Facchini Lellis, Adriana Bittencourt Campaner, Thiago da Silveira Manzione, Maria Clarissa de Faria Soares Rodrigues
Porokeratosis is a disorder of epidermal keratinization characterized clinically by a distinctive ridge-like border, and histologically by cornoid lamellae. The known clinical variants of porokeratosis are: classic porokeratosis of Mibelli, disseminated superficial (actinic) porokeratosis (DSAP), porokeratosis palmaris et plantaris disseminata, linear porokeratosis and punctate porokeratosis. In 1995, a seventh form was described as porokeratosis ptychotropica: a verrucous form resembling psoriasis involving the gluteal cleft presenting on the histological exam multiple cornoid lamellae...
July 2016: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/27504295/clinicopathological-study-of-non-infectious-erythaematous-papulosquamous-skin-diseases
#16
Sushma Hosamane, Muktha Pai, Thoppil Reba Philipose, Umaru Nayarmoole
INTRODUCTION: Papulosquamous diseases are characterized by scaly papules and plaques with similar clinical picture which amounts to confusion and hence, a definitive histopathological diagnosis goes a long way in treatment of such diseases. AIM: The aim of the study was to study the histomorphology of non-infectious, erythaematous, papulosquamous lesions of skin with clinicopathological correlation. MATERIALS AND METHODS: Skin biopsies from 150 clinically diagnosed/suspected non-infectious erythaematous, papulosquamous skin diseases were received in the Department of Pathology...
June 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27479112/ubiquitin-specific-peptidase-2-as-a-potential-link-between-microrna-125b-and-psoriasis
#17
T Wei, L Folkersen, E Biskup, N Xu, V Manfe, O Niazi, R Gniadecki
BACKGROUND: The extensive involvement of microRNA (miRNA) in the pathophysiology of psoriasis is well documented. However, in order for this information to be useful in therapeutic manipulation of miRNA levels, it is essential that detailed functional mechanisms are elucidated. miR-125b has previously been shown to be strongly associated with psoriasis, and presents as an obvious candidate for further investigation. OBJECTIVES: To elucidate the specific pathway and mechanism of interest in this association...
March 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/27468973/disseminated-superficial-actinic-porokeratosis-dsap-significant-improvement-after-local-administration-of-calcipotriol-betamethasone-gel
#18
Georgi Tchernev, Anastasiya Atanasova Chokoeva, Bogdana Ivanova, Hristo Mangarov, Nadezhda Georgieva Vidolova
Porokeratosis is defined as a disorder of keratinization characterized by one or more atrophic patches surrounded by a clinically and histologically distinctive hyperkeratotic ridgelike border called the cornoid lamella. Lesions are most commonly located on the sun-exposed sides of trunk and extremities, while exclusive facial involvement has been also reported. Despite that the exact risk of cutaneous malignancy developing in porokeratosis is unknown, it is confirmed by series of case reports, including squamous cell carcinoma, basal cell carcinoma and even melanoma...
March 2017: Wiener Medizinische Wochenschrift
https://www.readbyqxmd.com/read/27461455/biosimilars-in-psoriasis-clinical-practice-and-regulatory-perspectives-in-latin-america
#19
Claudia de la Cruz, André V E de Carvalho, Gladys L Dorantes, Angela M Londoño Garcia, Cesar Gonzalez, Matías Maskin, Nancy Podoswa, Jan S Redfern, Fernando Valenzuela, Joelle van der Walt, Ricardo Romiti
Latin American countries view biosimilar agents as an effective approach to curtail health-care expenditures while maintaining the safety and efficacy profile of their branded innovator comparators. To understand the complexities of the regulatory landscape and key therapeutic issues for use of biosimilars to treat moderate to severe psoriasis in Latin America, the International Psoriasis Council convened dermatology experts from Argentina, Brazil, Chile, Colombia and Mexico in October 2015 to review the definition, approval, marketing and future of biosimilars in each country and develop a consensus statement...
July 27, 2016: Journal of Dermatology
https://www.readbyqxmd.com/read/27335194/-sj%C3%A3-gren-s-syndrome-ss-a-review-of-the-subject-and-saliva-as-a-diagnostic-method
#20
REVIEW
Janett Carmen Luzmila Riega-Torres, Antonio Jaime Villarreal-Gonzalez, Luis Ángel Ceceñas-Falcon, Julio Cesar Salas-Alanis
Sjögren's syndrome is a chronic autoimmune disease whose main clinical manifestation is oral dryness (xerostomia) and ocular dryness (xerophthalmia). It is characterized by progressive mononuclear infiltration of the exocrine glands and can affect a variety of organ systems. The prevalence of primary Sjögren's syndrome varies from 0.01 up to 4.8%; this variability reflects differences in definition, application of diagnostic criteria, and geographic differences in age groups. The etiology of primary Sjögren's syndrome is unknown, but the interaction between genetic and environmental factors (viruses, hormones, vitamins, stress) is important...
May 2016: Gaceta Médica de México
keyword
keyword
110315
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"